氯氮平合并利培酮治疗难治性精神分裂症

目的：了解氯氮平全早培酮的治疗难治性精神分裂症的疗效和安全性。方法：２６例符合ＣＣＭＤ－２－Ｒ精神分裂症诊断标准且临床判断属于难治性病人，予氯氮平合并利培酮治疗，疗程８周，分别在治疗前及治疗后进行阳性与阴性症状量表（ＰＡＮＳＳ）和不良瓜症状量表（ＴＥＳＳ）评定。结果：合并治疗８周后部是性，阴性及一般精神病理分治疗前后均有显著差异。ＴＥＳＳＵ叫分治疗前后无显著差异。副反应主要为静坐不能，肌张力增高，

Combined treatment of refractory schizophrenia with clozapine and risperidone

Objective:To evaluate the efficacy and side effects of combined clozapine and risperidone in the treatment of refractory schizophrenia. Method:Twenty six patients with diagnosis of schizophrinia according to CCMD 2 R and proved refractory to standard treatment were treated with clozapine and risperidone for eight weeks. Subjects were assessed with the PANSS and TESS before and after treatment. Results:Overall successful rate after eight weeks was 65 3%. There were significant differences in the positive, negative and general psychopathology scores of PANSS between pre and post treatment(P<0 01). The main side effects were akathisia, increased muscle tone, insomnia, weight gain and blurred vision. Conclusion:Schizophrenic patients showing limited response to clozapine alone could gain further improvement with combined clozapine and risperidone treatment. Clients show good tolerance and compliance to the combination regime.